Medicines for adults with ADHD, and ‘Ozmpic’ for diabetics: the recommendations of the Health Basket Committee for 2024 have been submitted

The public committee for the expansion of the health services basket for 2024 submitted today (Thursday) its recommendations for the expansion of the health basket to the Minister of Health, Uriel Bosso. The committee, chaired by Prof. Dina Ben Yehuda, finished her work yesterday at night. The basket’s budget framework will be 650 million shekels, like last year, the largest addition to the basket since its inception in 1995.

Among the prominent treatments that will enter the basket this year: drugs for attention and concentration disorders in young adults; The popular drugs for type 2 diabetes ‘Ozmpic’ and ‘Rivalsus’, one of whose side effects is weight loss, have been approved for those diagnosed with diabetes; A wide and uniform genetic screening to detect carriers for pre-pregnancy genetic diseases; A hybrid-automatic system for monitoring sugar and injecting insulin for type 1 diabetes patients aged 18-40, which will replace sugar monitoring with a needle (with deductible); and a line of new drugs or the extension of eligibility for existing breast cancer drugs. A one-time budget will be dedicated to encouraging routine vaccination among populations with a low vaccination rate.

Due to the war, the committee convened and submitted its recommendations late, so the new technologies in Sel are expected to become available to the public only from mid-March, after the Ministry of Health formulates circulars for the use of the new treatments.

Among the drugs and treatments that will not be included in the basket are vaccines for the meningococcal bacterium and the RSV virus, a decision that provoked criticism from the Association of Pediatricians. An innovative gene therapy for Duchenne muscular dystrophy will not go into the basket either. It was also agreed that the drug paxlobide for corona patients will enter the basket temporarily for this year, and the drug remdesivir will be given to patients but will be financed from another source, not within the health basket.

Medications for ADHD in young adults

the drugs for attention deficit hyperactivity disorder (ADHD), Vyvanse ו-Lisdexaapproved for adults aged 18-28. requests totreatments forADHD in adults have been submitted for many years to the basket committee, and this year they were approved for the first time. What contributed to the committee’s decision this year was the war situation, and Health Minister Uriel Bosso’s commitment at the committee’s first meeting to “put emphasis on mental health.” According to the position of the Association of Psychiatrists submitted to the committee, there is a connection between ADHD and post-traumatic stress disorder.

The union’s position states that “Although not the entire population is expected to suffer from post-traumatic stress disorder (PTSD) following the Iron Swords War, an increase in the incidence of symptoms is expected Post-trauma, and it is known that ADHD is a risk factor for stress and PTSD. treatment of-ADHD can reduce the risk of post-traumatic stress disorder.”

The issue caused controversy among the members of the committee. The supporters of including the drugs in the basket claimed that they would help young people who served in the reserves and were financially harmed by the war to enter studies and the job market. Another incentive to put the drugs in the basket this year is the entry of a generic version of Vyvanse into the market later this year, which will allow the drug to be administered at a lower cost. However, some members of the committee opposed the inclusion of the drugs in the basket at the expense of other treatments, arguing that adults can bear the cost of the drug.

The diabetes medications whose side effect is weight loss

The drugs for type 2 diabetes, Ozempic and Rivalsus (Rybelsus), will enter the basket for patients diagnosed with diabetes. they approved and popular today also for pre-diabetic patients, among other things because of the side effect of weight loss. But as mentioned, the funding will be given to diagnosed patients only. 5,691 patients are expected to receive the drugs through the health basket this year.

A wide genetic screening for couples in the pre-pregnancy phase

The committee approved a broad and uniform genetic screening to detect carriers for pre-pregnancy genetic diseases. The new broad survey will replace the policy of the basket of tests given today, which varies according to the genetic origin of the subjects. The reason for the change is the understanding that the younger generation is sectarianly involved. In addition, genetic tests that are currently provided as part of the Shaban (additional health services) with a deductible of hundreds of shekels will be added to the basket. 126 thousand patients are expected to be tested in the new survey this year

A system that will help diabetics aged 18-40

The committee approved a hybrid-automatic system for monitoring sugar and injecting insulin for type 1 diabetes patients aged 18-40, which replaces the blood sugar tests with a needle and the calculation of the insulin dose for an independent injection, with a deductible of NIS 50 per month.

This system is already included in the basket for children with diabetes, and according to the data received by the committee, it reduces the risk of getting out of balance and suffering from the complications of the disease even among the adults, and raises the patients’ standard of living. 4,252 patients are expected to receive the technology this year.

A line of new drugs for breast cancer

268 A million shekels, or about 40% of the basket’s budget, will be dedicated to cancer treatments. Among the cancer treatments, breast cancer (the most common type of cancer in Israel) stands out as the area for which the highest funding has been allocated, and the highest number of patients will be treated through it.

In addition, the treatment line of the drug will be advanced Verzenio of the “Eli Lilly” company, for the treatment of early type breast cancer HR+HER2 with positive nodes, for 642 patients (the highest amount of all cancer treatments entered) at a total cost of NIS 48.954 million; The indication of the biological drug was expanded Keytruda, of the ‘Mark’ company, which encourages the immune system to fight cancer cells, for patients with type 1 breast cancer Triple Negative at an earlier stage than the indication that was included in the basket until now, for 116 patients, at a total cost of 25.631 million shekels; and will be given the medicine Trodelvy of the ‘Gilad’ company, for the treatment of unresectable or metastatic breast cancer Triple Negative, For 116 patients, a total cost of NIS 17.739 million.

The most expensive treatment that will enter the basket this year is the medicine Vygart Of the company Argenx, which costs NIS 643,000 for each patient. The drug is intended for the treatment of the disease myatenia gravis, which damages the connection between nerves and muscles and causes muscle weakness, and will be given to 50 patients a year.

Out of the basket: vaccines for children and innovative treatment for muscular dystrophy

As every year, many treatments submitted to the committee did not make the final list. These are the prominent treatments that did not enter the basket this year:

The meningococcal and RSV vaccines were left out

The committee chose to leave the vaccine out of the basket Beyfortus of the ‘Snoofy’ company against the RSV virus, which causes the hospitalization of 4,000 children a year due to pneumonia, and the vaccine Bexero Of the company GSK Against the invasive meningococcal bacterium, which causes meningitis in children and young people, with 1-3 deaths per year.

For several members of the committee, it was important to put a vaccine in the basket, but during the night hours of the last day of discussions, when it became clear that for the purpose of meeting the budget of the basket, they would have to decide between introducing a vaccine and the drugs to treatADHDit was agreed that a new vaccine would not be introduced, and that a one-time budget from the basket budget surplus, created as a result of the late submission of the recommendations, would be dedicated to encouraging vaccination with the existing vaccines in the basket among populations with a low vaccination percentage.

The innovative treatment for muscular dystrophy raised doubts

the treatment the genetic Television of the “Serpeta” company for children with the rare muscular dystrophy ‘Duchen’ was rejected by the committee, even though the drug was ranked first by the Association for Child Neurology. However, it was approved by theFDA just this year And yet is not provided in the public health system of any country in the world.

The rejection had two main reasons: doubt about the effectiveness, and the price. The committee members were skeptical about the evidence from the clinical trial conducted by the company. Although the performance of the children who received the drug was higher than the performance of the children who did not receive it, it was not enough to pass the threshold of statistical significance. About 24 children aged 4-6 were expected to receive the drug this year, after which eight more patients were expected to join each year.

In addition to the doubt expressed by the committee regarding the effectiveness of the drug, its price – 8.75 million shekels for each patient, It is the highest among the drugs discussed in the drug basket committee ever. As one of the members of the committee said, “one more child from the plan who will be entitled to the medicine, will collapse the annual budget of his health fund”.

The Ministry of Health tried to negotiate with the company to lower the price of the drug, without success.

The drugs for Corona: a temporary solution instead of permanent funding

Corona drugs Remdesivir and-Paxlovid: funded in 2020-2022 from the dedicated Corona budgets. This winter there was a disagreement between the Ministries of Health and Finance regarding the source of funding for the drugs, and this year these came up for discussion in the basket committee for permanent funding.

The basket committee members argued in the discussions that it is not appropriate to include in the permanent basket budget medicines for the plague, which cannot be expected to be needed in the future. In the end, it was decided that instead of including the drugs in the basket budget, the financing of thePaxlovid will come from a one-time budget of the basket budget surpluses, andRemdesivir will be financed from another source by the Ministry of Finance.

“Complex reality – between emergency and routine”

the minister of Health Uriel his boss He said upon submitting the committee’s recommendations: “Since October 7, the Ministry of Health has been facing a very complex reality – between an emergency and routine. On the one hand, the health system is mobilized and harnessed to military activity. This is reflected in the intensive treatment of the many casualties among civilians and combatants, in a large investment in the field of mental health, In the physical rehabilitation and daily dealing with medical challenges that the war poses to the entire population, alongside preparing for the expansion of combat and extreme scenarios on the home front and at the front.

“On the other hand, we are committed to continuing, as much as possible and with the necessary adjustments, other important processes for public health, including ensuring the provision of innovative treatments and medicines to patients in Israel. Faced with this reality, the basket committee set out and worked around the clock in order to come up with recommendations that manage to balance Among the complex needs are social sensitivity and human compassion.”

According to Minister Bosso, “I am proud that despite the budgetary challenges posed by the war, we succeeded with the assistance and involvement of the Shas Chairman Rabbi Aryeh Deri To allocate an additional budget in the amount of approximately 650 million shekels to the medicine basket this year as well. This is a day with tremendous meaning for many citizens of Israel. This year, too, we are standing by the side of the patients and caregivers, and can say with great pride that the Israeli basket is one of the most extensive, advanced and best in the world.”

Director General of the Ministry of Health, Moshe Bar is a good sign: “This is a complex year for the State of Israel. The health system operated and continues to operate at a very high intensity as of October 7. Along with treating the many wounded and providing mental support for all those who need it, we are required to continue to respond to Israelis in routine areas as well. We continue to provide Responding to patients as well as working to prevent diseases and for public health.

“Today we maintain and realize one of the most important principles in the state health insurance law – mutual guarantee. We guarantee availability of the most advanced technologies universally to all residents. On this day we always look back with pride and satisfaction at the fact that we provided a response to the patients, but we also remember the patients who did not receive answer this year, and we hope that we will be able to answer them next year.”

chairman of the committee, Prof. Dina Ben Yehuda: “I thank the Minister of Health and the Ministry of Health for the trust you have placed in me. To chair the Basket Committee, this is one of the most complex challenges in the health care system. I thank the professional team in the Technology Division who prepared the materials for the discussions. I thank the members of the committee for the professional discussions.

“The members of the committee came from a wide range of fields of knowledge and occupation – medical, managerial, economic, public and social. All of them were reflected in the committee’s considerations. Despite the differences, I felt in all the discussions that what unites us all in the decision-making process was the observance of the rules of ethics and compassion.

“I believe that we have succeeded in achieving a diverse and most advanced update to the publicly funded healthcare basket for the citizens of Israel. We have given many medicines and technologies aimed at preventing diseases, but also many medicines that provide health, relief from suffering and prolong life.

“For me, this is also a sad day for those patients for whom we were not able to include new technologies, and I have every hope that the technologies for them will be included in next year’s drug basket.”

Head of the Medical Technologies, Information and Research Division at the Ministry of Health and the head of the committee, Dr. Osnat Luxenburg: “I thank the Minister of Health Uriel Bosso, the Director General of the Ministry of Health, Moshe Bar Siman Tov, for the trust they have placed this year in the Technology Division of the Ministry of Health to lead this important and complex national process. All along the way, the patients in need of medicines and technologies stood before our eyes.

“We did the maximum possible to provide the best response, weighing between the urgent needs and the response to chronic disease states and the prevention of disease. We are sorry that it was not possible to respond to everyone, but we see it as our public mission to continue to promote the introduction of medicines and technologies into the health care basket, and already in the days These, we start the process of expanding the basket for next year.

For the full document of the committee’s recommendations – click here

The list of medicines that will be added to the health basket in 2024

Nephrology

• Jardiance and Forxiga treatment of chronic kidney disease – expansion of the framework of inclusion in the basket for patients with eGFR between 20-45 ml/min without albuminuria – 9,580 patients at a cost of 7.857 million NIS per year
• Jardiance and Forxiga treatment of chronic kidney disease – expanding the scope of inclusion in the basket – patients with eGFR between 75-90 ml/min and albuminuria approximately 200 mg/g or higher – 9,609 patients at a cost of 7.881 million NIS per year
• Jardiance for the treatment of chronic kidney disease patients, in accordance with the inclusion framework of: Forxiga chronic kidney disease with an albumin / creatinine ratio in the urine of
• 200 mg/g or more and eGFR between 25 and 75 ml/min, who are treated with a preparation from the ACE inhibitor family or
• ARB – no additional cost
• Tavneos for the treatment of severe and active GPA (Granulomatosis with polyangitis) or MPA (Microscopic polyangitis) for patients with renal involvement with an eGFR lower than 30 – 36 patients at a cost of 8.712 million NIS per year

Pulmonary medicine

• Spiriva Respimat, Enerzair, Trelegy ellipta, Trimbow – an inhaler for the treatment of severe asthma – 55,348 patients at a cost of NIS 6.788 million per year
• Dupixent and Nucala – injections for the treatment of severe eosinophilic asthma – expansion of the inclusion framework in the basket for patients with blood eosinophilia at a level of 150-300 cells per microliter – at no additional cost
• Dupixent – injection for the treatment of severe eosinophilic asthma in children aged 6 and over – expansion of the inclusion framework in the basket – for patients with blood eosinophilia at a level of 150-300 cells per microliter – 4 patients at a cost of NIS 160,000 per
• Trimbow, Trelegy Ellipta inhaler for the treatment of chronic obstructive pulmonary disease – expanding the inclusion framework in the basket
• Cancellation of the FEV1 limit and the possibility of obtaining a prescription from a family doctor – at no additional cost Ultibro breezhaler, Spiolto Respimat, Anoro Ellipta for the treatment of chronic obstructive pulmonary disease – the possibility of obtaining a prescription from a doctor – at no additional cost
• Tyvaso for the treatment of pulmonary hypertension in patients with ILD – 49 patients at a cost of NIS 5.974 million per year
• Adempas for the treatment of hypothermia I saw my arteries – at no additional cost

dermatology

• Oluminant and Litfulo for the treatment of severe alopecia areata, which causes patchy baldness, in adults – 374 patients at a cost of 11.126 million NIS per year
• Litulfo for the treatment of severe alopecia areata in children from the age of 12 – 60 children at a cost of 1.786 million NIS per year
• Dupixent for the treatment of eczema – expanding the inclusion in the basket to treat patients with severe disease from six months to 11 years whose disease is not controlled after failure with topicals – 325 patients at a cost of 17.325 million NIS per year
• Spevigo for the treatment of psoriasis GPP – 14 patients at a cost of NIS 1.7 million per year
• Bimzelx for the treatment of moderate to severe psoriasis, as part of the inclusion in the basket of other biological treatments

Endocrinology

• Isturia for the treatment of endogenous Cushing’s syndrome after surgical treatment and treatment with two drugs and did not reach equilibrium or exhausted treatment for other reasons – 25 patients at a cost of NIS 2.548 million per year
• Ngelna for the treatment of growth disorders in children and adolescents due to insufficient secretion of growth hormone – at no additional cost
• Voxzogo – for the treatment of achondroplasia from the age of two years onwards until the closure of the growth plates – 56 patients at a cost of NIS 28.339 million per year

Gastroenterology

• Bylvay for the treatment of advanced familial intrahepatic cholestasis – 6 patients at a cost of 1.794 million NIS per year
• Livmarli for the treatment of cholestatic pruritus in Alagille syndrome patients – 11 patients with 4,436 children Omvoh for the treatment of moderate to severe ulcerative colitis according to the inclusion framework in the basket of biological preparations for the disease – at no additional cost
• Dupixent for the treatment of eosinophilic inflammation of the esophagus – 60 patients at a cost of 5.640 million NIS per year

diabetes mellitus

• Hybrid-automatic system, for continuous sugar monitoring and personalized insulin infusion in a closed circuit – expanding the framework of inclusion in the basket for adults aged 18 to 40 with type 1 diabetes with a deductible of 50 NIS per month – 4,252 patients at a cost of 29.486 million NIS per year
• FLASH technology for monitoring sugar for type 2 diabetes patients – final push for inclusion in the basket – NIS 19 million per year
• Jardiance for the treatment of type 2 diabetes for children aged 10 and over – 46 children at a cost of NIS 31,000 per year
• Rybelsus and Ozempic for the treatment of type 2 diabetes in accordance with the framework of inclusion in the basket of drugs from the family of GLP1 analogs 5,691 patients at a cost of 14.704 million NIS per year

genetics

• A broad, uniform genetic screening for the entire population to detect carriers of genetic diseases – for pre-pregnancy and delivery. Carrying out the test for women, and testing the man only if there was an abnormal finding in the woman (taking blood for all men (will enter the basket starting in September) – 126,000 subjects at a cost of NIS 43.843 million per year
• Invasive screening tests during pregnancy (placental cysts, amniotic fluid) – expansion of eligibility to women over the age of 32 – 3,446 are tested at a cost of NIS 9.963 million per year

Cardiology

• Repair of severe tricuspid leak in patients with heart failure without evidence of significant mitral disease, despite the exhaustion of the maximum medical treatment, and who are not suitable for surgery and have suitable valve anatomy – 200 patients at a cost of NIS 24,336 per year
• Evkeeza for the treatment of cholesterol reduction in patients with homozygous familial hypercholesterolemia – without additional cost Jardiance for the treatment of heart failure – expanding the framework of inclusion in the basket in patients with a preserved ejection fraction – deleting the Sipa: “who remain symptomatic despite optimal treatment for their disease. In this regard, optimal treatment will include drugs from the RAS inhibitor family (ACE inhibitor ARB family) and beta blockers.” – at no additional cost
• Forxiga for the treatment of heart failure – expanding the inclusion framework in the basket in accordance with Jardiance’s inclusion criteria
• Medical food
• MSUD Cooler 15 for MSUD patients from age 3 onwards – 61 patients at a cost of NIS 2.555 million per year
• Novasource Renal for kidney disease patients treated with dialysis – at no additional cost
• Perative for tube feeding patients in metabolic syndrome, for patients suffering from wounds, and in children aged 3-13 with complete tube feeding after failure of standard formulas – at no additional cost
• Neurology
• Vyvgart and Ultomiris for the treatment of myasthenia gravis after exhausting previous lines of treatment including IVIG and Rituximab – 50 patients at a cost of NIS 31.942 million per year
• Kesimpta for the treatment of relapsing multiple sclerosis – at no additional cost
• Mayzent, Mavenclad, Ocrevus, Kesimpta, Vumerity, Gilenya, Fingolimod, Finolim, Avonex, Rebif, Betaferon, Tysabri for the treatment of multiple sclerosis type SPMS – 971 patients at a cost of 43.641 million NIS per year
• Rybrila for the treatment of severe chronic diarrhea in children and adolescents with chronic neurological disorders – 567 patients at a cost of 8.833 million NIS per year
• Fintepla for the treatment of convulsions due to Lennox Gastaut syndrome in accordance with the inclusion framework in the Epidiolex basket – at no additional cost
• psychiatry
• Vyvanse and Lisdexa for the treatment of ADHD in adults aged 18-28 (to be introduced in July 2024) – 91,752 patients at a cost of 44.530 million NIS per year
• Vyvanse and Lisdexa for the treatment of ADHD in children in accordance with the inclusion framework in the Attent basket (will be included in July 2024) – at no additional cost
• Vyvanse and Lisdexa for the treatment of severe compulsive eating disorder
• Rexulti for the treatment of schizophrenia – expanding the framework of inclusion in the basket for adolescents aged 13 and over – 42 patients at a cost of NIS 100,000 per year

Hematology

• Enjaymo for the treatment of hemolysis in Cold agglutinin disease patients as a second line of treatment – 17 patients at a cost of 6.824 million NIS per year
• Zokinvy Treatment of Hutchinson-Gilford Progeria Syndrome or – Progeroid Laminopathies 2 patients at a cost of NIS 1.121 million per year

Otolaryngology

Cochlear (cochlear) implant for the treatment of asymmetric deafness – expanding the framework of inclusion in the basket for children up to the age of 18, for patients suffering from asymmetric deafness in one of the following situations:

1. when one ear is deaf and the other ear is hearing impaired;
2. When there is a severe or moderate asymmetric decrease in hearing in at least one ear

Infectious diseases

Livencity for the treatment of CMV that does not respond to treatment or is resistant to existing treatment in solid organ transplant recipients or bone marrow transplant recipients – 30 patients at a cost of NIS 7.913 million per year

Rheumatology

• Cosentyx for the treatment of Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis as a second line after failure of a TNF inhibitor
• Xeljanz for the treatment of Polyarticular Juvenile Idiopathic Arthritis, Juvenile Psoriatic Arthritis as a second line after failure of a TNF inhibitor – 120 patients at a cost of NIS 1.136 million per year

Oncology – solid tumors

• Comprehensive molecular genomic profile (CGP) of solid tumors for the purpose of adjusting treatment for patients with advanced/metastatic solid cancer or at high risk of recurrence – expanding the inclusion framework in the basket also for endometrial cancer – 850 subjects at a cost of 3.6 million NIS per year
• A test to diagnose the lack of DPD (Dihydropyrimidine Dehydrogenase) enzyme activity in patients who are candidates for treatment with drugs from the fluoropyrimidine family – 5,300 subjects at a cost of 2.521 million NIS per year
• Opdivo as an adjuvant treatment for stage IIB, IIC, III melanoma after complete surgical removal – at no additional cost
• Opdivo, Opdualag, Keytruda as a treatment for unresectable or metastatic melanoma – expanding the scope of inclusion
• Bessel – an additional immunotherapy treatment line in the combination of Nivolumab + Ipilimumab in patients whose disease has progressed after first-line treatment with Pembrolizumab or Nivolumab monotherapy – 31.5 patients at a cost of 6.866 million NIS per year
• Keytruda, Lenvima – treatment for advanced endometrial cancer that has progressed after previous treatment.
• In patients with pMMR type disease who are not candidates for curative treatment through surgery or radiation – 83 patients at a cost of NIS 20.796 million per year
• Keytruda for the treatment of lung cancer – as adjunctive treatment after resection and treatment with platinum-based chemotherapy, in adult patients with NSCLC type lung cancer stage (cm 4 ≥T2a) IB stage II or stage IIIA, in patients with PDL1 value of 50% or more – at no additional cost
• Opdivo as a first-line treatment for unresectable, advanced or metastatic squamous cell esophageal cancer, in combination with chemotherapy in patients with PDL1 of approximately 50% or higher, and PDL1 testing for the treatment candidates – 27 patients at a cost of 4.723 million NIS per year
• Abraxane for the treatment of metastatic pancreatic cancer as a first line of treatment – 240 patients at a cost of 6.171 million NIS per year
• Imfinzi, Imjudo for first-line treatment of unresectable or advanced liver cancer of the HCC type, combined treatment of the two drugs – no additional cost Pemazyre treatment of cholangiocarcinoma, locally advanced or metastatic, with FGFR2 fusion or rearrangement after at least one other previous line of treatment – 10 patients at a cost of NIS 2,594 per year
• Tafinlar, Mekinist in combination as a first line of systemic treatment for pediatric low grade glioma with a BRAF V600E mutation – 6 patients at a cost of 1.267 million NIS per year
• Tecentriq for the treatment of adults and children over 2 years of age with unresectable or metastatic Alveolar soft part sarcoma – 1.5 patients at a cost of NIS 311,000 per year
• Avaykit for the treatment of unresectable or metastatic GIST sarcoma with exon 18 mutation – 9.7 patients at a cost of 4.068 million NIS per year
• Cabometyx for the treatment of differentiated thyroid cancer in an advanced local or metastatic stage, after exhausting radioactive iodine treatment, which progressed during or after previous systemic treatment – 20 patients at a cost of NIS 2.109 million per year
• Lynparza for the treatment of castration-resistant metastatic prostate cancer in patients with a BRCA type mutation whose disease has progressed after previous treatment with Enzalutamide or Abiraterone, including BRCA testing – 25 patients at a cost of 4.643 million NIS per year
• Keytruda for the treatment of BCG unresponsive NMIBC bladder cancer with a localized tumor, in patients who are not suitable or avoid undergoing cystectomy – 47 patients at a cost of 5.438 million NIS per year
• Verzenio for adjunctive treatment of early breast cancer, positive for hormonal receptors HER2, negative, with positive nodes, at increased risk of disease recurrence. In combination with endocrine treatment – 642 patients at a cost of NIS 48.954 million per year
• Keytruda for the treatment of high-risk triple negative early breast cancer. In combination with chemotherapy in the neoadjuvant phase, and as monotherapy as a complementary treatment after surgery – expanding the framework of inclusion in the basket for patients in the T2N0 phase – 116 patients at a cost of 25.631 million NIS per year
• Trodelvy for the treatment of unresectable or metastatic cancer of the triple negative type, after at least 2 systematic lines of treatment, at least one of them in an advanced stage of the disease – 116 patients at a cost of 17.739 million NIS per year
• Hemato-oncology
• Avaykit for the treatment of advanced systemic mastocytosis – 8 patients at a cost of NIS 2.885 million per year
• Cotellic for the treatment of histiocytic neoplasms – 30 patients at a cost of NIS 6.462 million per year
• Rezurock for the treatment of chronic anti-graft disease after the failure of two systemic lines of treatment and beyond, including the extraction of treatment with Ruxolitinib – 65 patients at a cost of 14.989 million NIS per year
• Xospata for the treatment of relapsed or refractory acute myeloid leukemia with FLT3 mutation – 40 patients at a cost of 14.556 million NIS per year
• Imbruvica, Venclexta in combination, for the treatment of chronic lymphocytic leukemia as first line treatment – at no additional cost
• Adcetris for the treatment of CD30+ Hodgkin lymphoma for patients with advanced disease in combination with chemotherapy, as a first line of treatment – expansion of the basket inclusion framework for 18-60 year olds with IPS 3 and above – 42 patients at a cost of 6.601 million NIS per year
• Lunsumio for the treatment of recurrent or refractory follicular lymphoma after two or more previous lines of treatment – 38 patients at a cost of 10.777 million NIS per year
• Epkinly, Columvi for the treatment of relapsed or refractory DLBCL lymphoma after at least 2 previous lines of treatment – 96 patients at a cost of NIS 27.338 million per year